Ascendis Health Past Earnings Performance
Past criteria checks 0/6
Ascendis Health has been growing earnings at an average annual rate of 22.7%, while the Pharmaceuticals industry saw earnings growing at 6.4% annually. Revenues have been declining at an average rate of 33.8% per year.
Key information
22.7%
Earnings growth rate
23.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -33.8% |
| Return on equity | -7.9% |
| Net Margin | -3.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Ascendis Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,496 | -51 | 629 | 0 |
| 30 Sep 23 | 1,516 | -168 | 632 | 0 |
| 30 Jun 23 | 1,535 | -286 | 635 | 0 |
| 31 Mar 23 | 1,547 | -277 | 624 | 0 |
| 31 Dec 22 | 1,559 | -268 | 560 | 0 |
| 30 Sep 22 | 1,559 | -513 | 592 | 0 |
| 30 Jun 22 | 1,559 | -759 | 624 | 0 |
| 31 Mar 22 | 1,833 | -1,211 | 740 | 0 |
| 31 Dec 21 | 2,107 | -1,663 | 856 | 0 |
| 30 Sep 21 | 1,966 | -1,677 | 798 | 0 |
| 30 Jun 21 | 1,825 | -1,691 | 741 | 0 |
| 31 Mar 21 | 761 | -1,985 | 352 | 0 |
| 31 Dec 20 | -304 | -2,280 | -36 | 0 |
| 30 Sep 20 | 949 | -1,896 | 347 | 0 |
| 30 Jun 20 | 2,203 | -1,512 | 730 | 0 |
| 31 Mar 20 | 5,761 | -1,372 | 1,712 | 0 |
| 31 Dec 19 | 5,417 | -1,884 | 1,685 | 0 |
| 30 Sep 19 | 5,644 | -1,836 | 1,713 | 0 |
| 30 Jun 19 | 5,872 | -1,788 | 1,740 | 0 |
| 31 Mar 19 | 5,494 | -912 | 1,732 | 0 |
| 31 Dec 18 | 5,116 | -36 | 1,724 | 0 |
| 30 Sep 18 | 5,313 | -1 | 1,721 | 0 |
| 30 Jun 18 | 5,511 | 34 | 1,717 | 0 |
| 31 Dec 17 | 7,152 | 406 | 1,780 | 0 |
| 30 Sep 17 | 6,780 | 373 | 1,694 | 0 |
| 30 Jun 17 | 6,409 | 340 | 1,609 | 0 |
| 31 Dec 16 | 5,154 | 204 | 1,343 | 0 |
| 30 Sep 16 | 4,534 | 181 | 1,187 | 0 |
| 30 Jun 16 | 3,914 | 159 | 1,030 | 0 |
| 31 Mar 16 | 3,636 | 204 | 955 | 0 |
| 31 Dec 15 | 3,354 | 253 | 902 | 0 |
| 30 Sep 15 | 3,085 | 231 | 848 | 0 |
| 30 Jun 15 | 2,817 | 210 | 794 | 0 |
| 31 Dec 14 | 2,289 | 171 | 737 | 0 |
| 30 Sep 14 | 1,954 | 154 | 643 | 0 |
| 30 Jun 14 | 1,618 | 136 | 550 | 0 |
| 31 Dec 13 | 950 | 68 | 303 | 0 |
| 30 Sep 13 | 774 | 39 | 251 | 0 |
| 30 Jun 13 | 598 | 9 | 199 | 0 |
Quality Earnings: ASC is currently unprofitable.
Growing Profit Margin: ASC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASC is unprofitable, but has reduced losses over the past 5 years at a rate of 22.7% per year.
Accelerating Growth: Unable to compare ASC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.4%).
Return on Equity
High ROE: ASC has a negative Return on Equity (-7.86%), as it is currently unprofitable.